PolyPid has received a Nasdaq notification for failing to meet the minimum stockholders' equity requirement, reporting $2.158 million against the required $2.5 million.

Atezolizumab, bevacizumab, and GEMOX (gemcitabine plus oxaliplatin) demonstrated efficacy and safety in treating advanced biliary tract cancer (BTC).

In 1974, Dr. Lawrence Einhorn at Indiana University pioneered a cisplatin-based chemotherapy regimen, revolutionizing testicular cancer treatment.

Oncology leads as the top therapy area for both planned and expected clinical trials in 2024, indicating a strong focus on cancer research and development.

Denali Therapeutics and Takeda Pharmaceutical Company have initiated a phase 1/2 clinical trial for FTD caused by GRN mutations at the University of Pennsylvania, marking the first U.S.-based trial site. The study evaluates the safety and tolerability of DNL593, aiming to address progranulin deficits in FTD-GRN patients.

Gate Neurosciences and the University of Pittsburgh have started a Phase II trial to assess apimostinel's ability to prolong antidepressant effects when combined with a digital therapeutic.

Biodexa Pharmaceuticals has enrolled the first patient in a Phase 2 study evaluating tolimidone, a selective Lyn kinase activator, for Type 1 diabetes treatment.

Aviceda Therapeutics has completed enrollment for its Phase 2b SIGLEC study evaluating AVD-104 for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

BioVie Inc. will present the design of its Phase 2 trial of bezisterim for Long COVID at the Demystifying Long COVID International Conference.

The European Medicines Agency's CHMP has recommended Palforzia for treating peanut allergies in toddlers aged 1-3, marking a potential expansion of its use.

NanoVibronix has successfully completed the pilot phase of a randomized controlled trial for UroShield, a device designed to prevent catheter-associated urinary tract infections (UTIs).

The PERSYST study, led by the University of Adelaide, is resolving variants of uncertain significance (VUS) using skin samples to extract RNA from disease-causing genes.

Circle Pharma will present late-breaking data at AACR 2025 showing how their novel cyclin A/B RxL inhibitors disrupt DNA repair pathways and affect mitotic progression in E2F-high cancers.

Breakthrough T1D has awarded $2.8 million over three years to create the U-M-OHSU Cardiorenal Center of Excellence, expanding research on heart and kidney complications in type 1 diabetes patients.

Towa Pharmaceutical and Kyoto University have initiated the final phase of a clinical trial testing bromocriptine, a Parkinson's drug, as a potential treatment for familial Alzheimer's disease using innovative iPS drug discovery methods.

Acuitas Therapeutics, Children's Hospital of Philadelphia, and University of Pennsylvania successfully delivered the world's first personalized LNP-delivered CRISPR gene-editing therapy to an infant with urea cycle disorder, with no adverse events reported.

Polyrizon Ltd. has appointed Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs, marking a strategic move to bolster its clinical trial efforts for PL-14, set to begin in 2025. With over a decade of experience in the medical device and pharmaceutical industries, Dr. Meir's expertise in regulatory strategy and clinical affairs is expected to significantly contribute to the company's mission of delivering innovative intranasal hydrogels.

Three-year follow-up data from the phase 3 TRANSFORM trial demonstrates lisocabtagene maraleucel (liso-cel) significantly improved event-free survival with a median of 29.5 months versus 2.4 months with standard of care in relapsed large B-cell lymphoma.

AION Healthspan has initiated a Phase I/II clinical trial for REJUVXL, a novel cell therapy targeting inflammation, fibrosis, and immune dysregulation in Stage 3 Chronic Kidney Disease patients.

The FDA has cleared Northwestern University's IND application for Calidi Biotherapeutics' CLD-101, a stem cell-based platform delivering oncolytic viruses for treating high-grade glioma, with Phase 1b/2 trials starting late 2024.